rss
Ann Rheum Dis 66:548-550 doi:10.1136/ard.2006.058248
  • Concise report

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis

  1. Pirjo Tynjälä2,
  2. Päivi Lindahl3,
  3. Visa Honkanen2,
  4. Pekka Lahdenne2,
  5. Kaisu Kotaniemi1
  1. 1Department of Opthalmology, Rheumatism Foundation Hospital, Heinola, Finland
  2. 2Department of Pediatric Rheumatology, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
  3. 3Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland
  1. Correspondence to:
    Dr P Tynjälä
    Research Unit, Hospital for Children and Adolescents, Biomedicum 2 Helsinki, 5th Floor, PO Box 448 (Tukholmankatu 8A) Helinski, 00029 HUS, Finland; pirjo.tynjala{at}hus.fi
  • Accepted 22 October 2006
  • Published Online First 26 October 2006

Abstract

Objective: To evaluate the efficacy of anti-tumour necrosis factor (anti-TNF) treatment in juvenile idiopathic arthritis (JIA)-associated uveitis.

Methods: 24 patients with uveitis taking etanercept and 21 taking infliximab were studied. The endpoint ophthalmological evaluation was at 24 months or at the termination of the first biological agent. The ocular inflammatory activity was graded on the basis of the number of anterior chamber cells.

Results: Of the 45 patients, uveitis improved in 14 (31%), no change was observed in 14 (31%) and the activity of uveitis increased in 17 (38%). Inflammatory activity improved more frequently (p = 0.047) in the patients taking infliximab than in those taking etanercept. The number of uveitis flares/year was higher (p = 0.015) in the patients taking etanercept (mean 1.4, range 0–3.2) than in those taking infliximab (mean 0.7, range 0–2). Uveitis developed for the first time while taking anti-TNF treatment in five patients—4 taking etanercept (2.2/100 patient-years) and 1 taking infliximab (1.1/100 patient-years).

Conclusions: During anti-TNF treatment, the ophthalmological condition improved in one-third of the patients with uveitis. In chronic anterior uveitis, associated with refractory JIA, infliximab may be more effective than etanercept.

Footnotes

  • Published Online First 26 October 2006

  • Competing interests: None declared.